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Hepatocellular carcinoma (HCC) is a relatively common
cancer and occurs mainly in patients with liver cirrho-
sis (85%-95%). A significant number of cases are, how-
ever, diagnosed in normal and noncirrhotic/nonfibrotic
livers. In contrast to HCC in a cirrhotic liver, noncir-
rhotic hepatocellular carcinoma (NC-HCC) predomi-
nantly occurs in young and healthy female patients in
their 30s, and the diagnosis is frequently made at an
advanced stage in the absence of a clear etiological fac-
tor.1-3 The same holds true for the uncommon fibrola-
mellar hepatocellular carcinoma (FL-HCC) variant.1-3
Several studies have shown that the 3-year overall
survival (OS) rates with different pharmaceutical,
radiological, and surgical therapies for HCC (if they are
adequately performed) are approximately 60%.4 After 3
years, the results of these treatments start to diverge
substantially with respect to OS and, most importantly,
with respect to disease-free survival (DFS). Long-term
follow-up (5-10 years) has clearly shown that surgical
resection is the only curative treatment for any kind of
HCC.2-5 With respect to very long-term DFS (>5 years),
liver transplantation (LT) offers the best results.2,4-6 In
order to be successful, surgery has to be adapted to
the tumor, the underlying condition of the patient, and
the patient’s liver. Liver resection and LT should have
complementary roles rather than competing ones, and
they should be associated with each other instead of
being opposed.5 Partial resection for HCC can be
considered only for patients with well-compensated
cirrhosis or fibrosis or with normal liver tissue. For
patients with decompensated liver disease, cirrhosis, or
a technically unresectable tumor, LT offers the best
chance for a cure. This option indeed addresses the
tumor as well as the underlying liver disease.
Despite the extensive experience with LT for the treat-
ment of HCC in patients with cirrhosis, the experience
with LT for the treatment of NC-HCC is anecdotal and is
limited to situations in which resection is not possible.
The aims of this study were as follows: (1) to ana-
lyze the results from recent series of partial liver
resections for NC-HCC, (2) to compare these results
with the results of LT for the same condition; and (3)
to propose an adaptation of the therapeutic algorithm
for NC-HCC on the basis of these analyses.
MATERIALS AND METHODS
A review of the literature on resection and LT for HCC
in patients with noncirrhotic livers was undertaken
with the MEDLINE, Science Citation, Embase, and
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Cochrane databases, and the following Medical Sub-
ject Headings keywords were used: hepatocellular car-
cinoma, hepatocellular cancer, liver transplantation,
liver resection, and normal liver. The search limit was
set to human studies in English between January
1995 and May 2011. One exception to the English
language limit of this analysis was the inclusion of
the 2006 yearly report on HCC from the Association
Française de Chirurgie.1 This monograph deals with a
French multicenter survey of the largest series of
patients undergoing partial liver resection for HCC in
a normal liver. Unfortunately, this huge experience
has never been published as a full article in the medi-
cal literature. Full texts were consulted after abstract
reviews. Duplicates, registries, and repeated series
from the same center were excluded from this review.
Only patients whose tumor characteristics were
described and for whom recurrence and outcome data
were available were finally included in this study.
Forty of 2859 articles were analyzed.
Twenty-six series on NC-HCC and liver resection
have been published1,7-32 (Table 1). Twenty of these
articles have relevant information on outcomes. Four-
teen have information on LT for NC-HCC. Although
approximately 300 patients have been reported to
have undergone transplantation for NC-HCC, the
analysis of the literature with respect to the impact of
LT on NC-HCC outcomes is particularly difficult
because only 8 transplant articles (dealing with only
27 patients) contain enough detailed information to
allow the analysis of risk factors for tumor recurrence.
Twenty-one of these patients had FL-HCC, and only 6
had classical HCC.33,34
The number of reported patients, the inclusion of
patients with viral hepatitis and/or alcoholic liver dis-
ease, the OS, DFS, and recurrence rates, the opera-
tive mortality, the risk factors influencing survival,
and tumor recurrence were analyzed. The literature
review of the transplant experience for NC-HCC was
completed for the 2010 consensus conference on LT
for HCC (Zurich, Switzerland) with data obtained
from a recent analysis of 105 liver recipients entered
into the audited European Liver Transplant Registry
(ELTR). The ELTR series included 62 patients (7 had
FL-HCC) who underwent primary LT for NC-HCC
and 43 patients (4 had FL-HCC) who underwent res-
cue LT for recurrence after partial liver resection.
The preliminary results of this analysis, which have
been published in abstract form,35 are included in
this article with the permission of the primary study
investigators (H.M. and R.J.P.), who were part of the
consensus conference committee. The detailed
results of this study, including all characteristics of
the studied patients, are currently under final anal-
ysis by the European Society for Organ Transplanta-
tion/ELTR boards. Because the tumor characteris-
tics of the NC-HCC and FL-HCC patients who
underwent LT were similar (except for the tumor size
and the Milan inclusion criteria), the results for NC-
HCC and FL-HCC were considered together in the
European Society for Organ Transplantation/ELTR
study in order to allow a more conclusive statistical
analysis.
RESULTS
Liver Resection7-13,15-32 (Table 1)
The articles reviewed for information on partial liver
resection for NC-HCC include 2263 patients; the num-
bers of patients in these series range from 20 to 254.7-
13,15-32 The results of the French multicenter study,1
which includes the world’s largest series of resections
for HCC arising in normal livers (ie, nonfibrotic and
noncirrhotic), are discussed separately. The larger
studies come from regions with high rates of hepatitis
B virus (HBV) and hepatitis C virus (HCV) infections.
The interpretation of the literature on liver resection for
NC-HCC is strongly confounded by differences in the
inclusion criteria. Almost no studies have dealt with
HCC in strictly normal livers. Some studies have
included only patients with noncirrhotic and nonfi-
brotic livers without underlying viral hepatitis or alco-
hol abuse; most reports, however, have included many
patients with viral hepatitis or evidence of alcohol
abuse. Moreover, almost no information about the
increasing risk factors of steatosis and/or steatohepati-
tis is available in these series. In these reports, the
rates of HBV and HCV infections ranged from 4.8% to
70% and from 2.5% to 68%, respectively; the incidence
of alcohol intake varied from 7.1% to 70%. It is, there-
fore, difficult to compare the data in these various
reports because of the different rates of the risk factors.
This observation is very important because it has been
estimated that approximately 30% of HCV-associated
HCCs develop before cirrhosis is established. Thus, the
presence of HCV and HBV infections certainly influen-
ces recurrence after resection as well as survival.
Patients with NC-HCC present late, so they usually
have large tumors. The mean/median sizes of the
tumors in the various studies ranged from 8 to 14 cm.
In most cases, the diagnosis was made when clinical
symptoms and signs related to the tumor mass (eg,
pain, discomfort, and a palpable mass) occurred. The
preserved liver function allowed more extensive liver
resections in these patients and made the achieve-
ment of R0 resection (macro- and microscopic tumor-
free resection margin) likely. Over the past few deca-
des, because of better selection criteria and surgical
techniques, the results of partial liver resection have
steadily and markedly improved. Computed tomogra-
phy–assisted liver volumetry, preoperative portal vein
embolization, anatomical surgery, intraoperative
ultrasound-guided surgery, and parenchymal transec-
tion with (intermittent) inflow occlusion or even total
vascular exclusion have all played important roles in
safely extending the boundaries of partial liver resec-
tion.33-36 Extensive liver resection, which leaves up to
20% of the normal functional liver volume, can be
performed quite safely in these patients; this is evi-
denced by the low operative mortality rate, which
ranges from 0% to 6.4%. The 1- and 5-year OS rates
LIVER TRANSPLANTATION, Vol. 17, No. 10, 2011 LERUT ET AL. S91
after liver resection for NC-HCC range from 62% to
97% and from 25% to 81%, respectively. The 1- and
5-year DFS rates range from 49% to 84% and from
24% to 59%, respectively. The enhanced feasibility of
large liver resections and the longer survival times
have shifted the attention of the liver community from
(early) perioperative mortality to (late) tumor recur-
rence. The reported rates of tumor recurrence, which
most frequently occurs in the liver (but less than in
patients with cirrhosis), range from 30% to 73%.
These worrisome numbers might be even higher
because systematic long-term follow-up is missing in
most reports. The early diagnosis of tumor recurrence
is important because it may allow repeat resection
with good long-term outcomes in up to 30% of
patients. Tumor recurrence, especially within 1 year,










(Months) Risk FactorsOS DFS
Sasaki et al.7 (1992) 48 68 54 44 NR NR
Bismuth et al.8 (1995) 68 40 33 59 NR NR
Smalley et al.9 (1988) 29 25 High histological grade, severe necrosis,
hepatomegaly, hemoperitoneum, and
adjacent organ involvement
Fong et al.10 (1999) 54 42 66 20 Tumor size, AFP level >2000 ng/mL,
and vascular invasion
Poon et al.11 (2000) 155 46 35 51 NR
Shimada et al.12 (2000) 65 65 40 NR NR
Nagasue et al.13 (2001) 126 50 31 NR Portal vein invasion, HCV infection,
blood loss, intrahepatic metastases,
and resection margin
Belghiti et al.15 (2002) 53 50 Vascular invasion, poor differentiation,
and tumor diameter
Chen et al.16 (2003) 254 36 24 57 12 Multiple tumors, blood transfusion,
resection margin, and liver function
Grazi et al.17 (2003) 135 51 46 30 28 Blood transfusion and age >60 years
Verhoef et al.18 (2004) 22 68 56 Microvascular/macrovascular
invasion and lymph node invasion
Chang et al.19 (2004) 222 53 37 59 52 Advanced TNM stage
Lang et al.20 (2005) 83 30 63 25 Vascular invasion
Dupont-Bierre
et al.21 (2005)
88 44 41 25 Multiple tumors, macroscopic
vascular invasion, and nonuse of
adjuvant 131I-iodized oil
Laurent et al.22 (2005) 108 29 43 52 7 Blood transfusion, absence of
tumor capsules, satellite nodules,
and resection margin <1 cm
Cherqui et al.1 (2006) 586 53 40 60 >12 Tumor size >5 cm, number of tumors,
microvascular/macrovascular invasion,
poor differentiation, and R0 resection
Capussotti et al.23 (2006) 47 34 31 Tumor size >10 cm, satellite
nodules, and resection margin
Eguchi et al.24 (2006) 29 65 56 NR
Taura et al.25 (2007) 127 81 56 60 Tumor burden, vascular invasion,
and AFP level
Hubert et al.26 (2007) 29 71 59 38 42 Age >50 years, poor differentiation,
and satellite nodules
Bège et al.27 (2007) 116 40 33 65 79 Resection margin, vascular
invasion, and HBV infection
Lubrano et al.28 (2008) 20 64 58 40 NR Resection margin and
perioperative cytolysis
Rayya et al.29 (2008) 54 48 27 24 NR
Xu et al.30 (2008) 96 48 33 73 57 TNM staging
Sotiropoulos
et al.31 (2009)
92 40 25 62 28 Resection margin, vascular
invasion, and TNM staging
Smoot et al.32 (2011) 143 38 42 58 27 Multiple tumors (2), poor
differentiation grade, age >65 years,
blood transfusion, and male sex
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is predictive of poor OS and is a major cause of death.
It remains unanswered whether recurrence is due to
de novo cancer in a diseased liver (especially in HBV-
and HCV-infected patients) or to the evolution of
micrometastases. Several factors, such as daughter or
satellite nodules, multiple tumors, microvascular/
macrovascular invasion, R1 (microscopic tumor inva-
sion of resection margin) resection, and a short inter-
val (usually 1 year) between resection and appear-
ance, are predictive of recurrence and, therefore, favor
the latter hypothesis.
R0 resection has the greatest impact on OS and
DFS. Other clinical and pathological factors that sig-
nificantly influence OS and DFS are intrahepatic me-
tastases (also called daughter or satellite nodules or
multiple tumors), tumor capsule and lymph node
involvement, microvascular/macrovascular invasion,
the absence of a tumor capsule, perioperative blood
loss, and blood product use. The significant impact of
blood transfusions on outcomes, which has been
observed by several Western and Eastern groups,
underlines the importance of adequate surgical techni-
ques. Blood transfusions may be a surrogate marker
of other factors, such as larger tumors requiring larger
resections or the presence of an underlying liver dis-
ease with an associated coagulopathy; the effects of
blood transfusions could also be related to an immu-
nomodulatory effect that possibly stimulates tumor
growth. Although an age greater than 60 or 65 years,
elevated preoperative levels of aminotransferases,
resection margins < 1 cm, poor tumor differentiation,
HBV and HCV infections, elevated alpha-fetoprotein
(AFP) levels, and the nonuse of adjuvant, intra-arterial
131I-iodized oil injections have all been correlated with
unfavorable outcomes, they seem to have less prog-
nostic value. Interestingly, the tumor size has not
been a predictor of survival in several studies.
The French multicenter NC-HCC study, which
includes 586 patients, identified the tumor size (>5
cm), the number of tumors, microvascular/macrovas-
cular invasion, poor tumor differentiation, and R0
resection as significant negative prognostic factors.1
The 5-year OS rate was 53%. The 5- and 10-year DFS
rates were 40% and 30%, respectively. Unfortunately,
this high-volume study suffers from incomplete data
for many patients.
The very recently published retrospective study of
the larger Mayo Clinic series, which includes 143
well-documented NC-HCC patients undergoing par-
tial liver resection, is particularly interesting in the
context of this consensus conference publication.32
The median DFS time was 2.4 years; the 5-year OS
and DFS rates were 38% and 42%, respectively.
Despite a mean tumor diameter of 10.3 cm, macro-
vascular invasion and microvascular invasion were
present in only 13% and 8% of the cases, res-
pectively. This finding suggests that vascular inva-
sion may be a delayed feature of the intrahepatic
growth of HCC in a noncirrhotic liver. The presence
of 2 or more tumors (and thus not the tumor diame-
ter) was the only independent predictor of tumor
recurrence. Multiple tumors, male sex, an age >65
years, and a high histological grade were predictors
of OS. Because 75% of the recurrences occurred
in the liver, we can rightly address whether LT
would have been a better treatment for the high-risk
patients.32
The aforementioned risk criteria and considerations
could be used preoperatively to identify which
patients would most likely benefit from surgery and
eventually from primary or salvage transplantation
and which ones would be suitable candidates for ad-
juvant therapy.
In summary, the occurrence and presentation of
NC-HCC are well documented, and liver resection is
currently still the preferred therapeutic option when-
ever it is technically feasible. These young patients
usually tend to present late with large tumors, and
because of their relatively good liver function, they are
able to tolerate extensive liver resections. Extensive
operations can nowadays be performed safely with
acceptable long-term OS. Several risk factors that
have an impact on OS and DFS have been identified.
Tumor recurrence after resection continues to be a
major problem, and this indicates that there may be a
place for adjuvant treatment and/or LT in the treat-
ment of these patients.
LT37-42 (Table 2)
In 1999, Houben and McCall33 published the reported
experience with LT for HCC in patients without an
underlying disease (1966-1998). One hundred twenty-
six LT procedures were reported in 16 articles. The
results were very poor: the 5-year OS rates for NC-
HCC and FL-HCC patients were 11.2% and 39.4%,
respectively. This analysis unfortunately could not
identify any prognostic factors. The authors con-
cluded that LT should not be proposed for patients
with NC-HCC and should be proposed only for very
select patients with FL-HCC. These conclusions
clearly influenced the LT community because patients
with NC-HCC are currently only rarely considered for
LT. The reasons for this are multiple: (1) the reluc-
tance of liver surgeons to take into consideration the
possibility of LT as an initial therapeutic option; (2)
the common scenario in which these tumors are al-
ready beyond the Milan criteria (designed for patients
with HCC and cirrhosis) at presentation; (3) the fear
that LT followed by immunosuppression will favor tu-
mor recurrence; (4) the notion of utility, which
restricts transplantation in an era of organ shortages
to those patients who will benefit the most from LT
(ie, those presenting with liver failure and less
advanced tumors); and (5) the fact that patients with
NC-HCC do not benefit from an exception status in
the Model for End-Stage Liver Disease–based liver
allocation system.
The high incidence of tumor recurrence after
extended resection and the (sparse) reports of long-
term DFS after LT for tumor recurrence after liver
resection challenge the concept that liver resection is
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the treatment of choice for all patients with NC-HCC.
It is conceivable that LT as an initial option could
offer better outcomes to some patients with NC-HCC
in comparison with partial liver resection. The afore-
mentioned risk factors that are associated with a high
recurrence rate after liver resection could be very
helpful in identifying subgroups of NC-HCC patients
who would benefit from LT. The Milan criteria (1
lesion < 5 cm or 3 lesions < 3 cm), which have been
validated in the therapeutic algorithm for HCC in
patients with cirrhosis, are not applicable to patients
with NC-HCC because virtually all these patients have
tumor diameters and numbers exceeding these crite-
ria. Lymph node invasion and vascular invasion are
the main predictors of recurrence and DFS after LT.
An in-depth analysis of 27 well-documented NC-HCC
patients who underwent LT (including 21 FL-HCC
patients) and 62 ELTR patients who underwent pri-
mary LT for unresectable NC-HCC (including 7 FL-
HCC patients) supports this.38,39 In the ELTR study,
the actuarial 5-year OS and DFS rates were 49% and
49%, respectively. The median tumor diameter in this
patient group was 11 cm; only 5% of the patients ful-
filled the Milan criteria. In agreement with the data
obtained after partial liver resection, the tumor diame-
ter, more than 4 tumor nodules, and microvascular
invasion were not identified as significant determi-
nants of survival after LT, whereas macrovascular
invasion and lymph node invasion were (the 5-year
survival rate was 45% with invasion and 59% without
invasion). Similar observations were made in the
group of 43 ELTR patients (including 4 patients with
FL-HCC) who underwent salvage LT for intrahepatic
tumor recurrence after liver resection. The actuarial
5-year OS and DFS rates in this group were 58% and
48%, respectively. Despite a significantly lower me-
dian tumor diameter of 3 cm (in comparison with the
primary LT patient group), only 25% of these patients
fulfilled the Milan criteria. Macrovascular invasion
and a time period of less than 12 months between the
previous partial resection and tumor recurrence were
significant risk factors for poor outcomes. This short
time span probably reflects a more aggressive tumor
biology. Concise pathological assessments of the
resected tumor and the nontumor liver tissue could
thus be very helpful in identifying those patients with
a high risk of tumor recurrence after liver resection
and LT.
In summary, because the incidence of tumor recur-
rence after (extended) liver resection is high and res-
cue LT for tumor recurrence can be curative, there is
a possible role for LT in patients with NC-HCC. Mac-
rovascular invasion, lymph node invasion, and an
interval of less than 12 months between the previous
partial resection and recurrence (in the case of tumor
recurrence) are significant risk factors for poor out-
comes. The tumor diameter and the Milan criteria do
not significantly affect outcomes.
Separate Note on FL-HCC43-50
Because the analysis of the literature shows that NC-
HCC and FL-HCC are still perceived differently on
account of their different clinical presentations,
courses, imaging results, and outcomes, some brief
remarks about this tumor variant are made here.
FL-HCC is a very rare and well-differentiated HCC
tumor variant that accounts for 0.8% to 1% of all
HCCs. This tumor is slow-growing and occurs only in
young patients with a normal liver. FL-HCC frequently
expresses the marker des-gamma-carboxyprothrom-
bin (DCP); AFP is expressed in less than 10% of these
TABLE 2. Literature Review of HCC Patients Without Cirrhosis Who Were Treated With LT
Study Patients (n)
5-Year Survival (%) Recurrence
Rate (%) Risk FactorsOS DFS
Houben and
McCall37 (1999)
126 FL-HCC: 39.4 >50 NR
NC-HCC: 11.2 >50 NR
Pichlmayr et al. (1995)40* 8 49 38 >1 tumor and lymph
node invasion
Figueras et al. (1999)41 5 60 20 NR
Schlitt et al. (1999)42 25 27 NR
Pinna et al.43 (1997)* 13 36.3 30.8 69.2 Tumor stage, macrovascular
invasion, and lymph
node invasion
El-Gazzaz et al.44 (2000)* 9 50 33 55 Tumor stage
Mergental et al.39 (2007)
Primary LT 62 49 49 Macrovascular invasion and
lymph node invasion
Rescue LT 43 58 48 Macrovascular invasion
and <12-month delay
between resection and LT
NOTE: Only series with 5 or more patients are included.
*FL-HCC only.
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patients. FL-HCC is said to be associated with a
(more) favorable prognosis.45-47 In fact, FL-HCC is an
aggressive tumor associated with a less than 50% 5-
year OS rate, even in resectable cases. There are sev-
eral reasons for this discrepancy and the frequently
optimistic results reported for FL-HCC: (1) the series
are usually small and lack statistical power; (2) the
diagnostic pathological triad necessary to unequivo-
cally diagnose this subtype of HCC is frequently miss-
ing; (3) FL-HCC often occurs in cirrhotic or abnormal
livers; (4) follow-up is frequently lacking; and (5) most
importantly, the outcomes of FL-HCC are mostly com-
pared to the outcomes of HCC in general.46,47 A liter-
ature review by Kakar et al.43 clearly showed that the
outcomes of FL-HCC and NC-HCC are similar when
same-stage diseases are considered; the outcomes of
FL-HCC are much better than the outcomes of HCC
with cirrhosis. The results of the ELTR study (unpub-
lished data, 2011) confirm these findings. These
observations, along with the fact that (1) FL-HCC did
not differ from other HCCs arising in a normal liver
with respect to any variable (except for the tumor
size and the Milan inclusion criteria)39 and (2) the
proliferative activities of these tumor variants (eg, as
determined by immunohistochemistry for Ki-67) were
also similar,35,43,44 explain why HCC in normal livers
and FL-HCC were deliberately pooled together in the
ELTR study. This allowed a valuable statistical eval-
uation of the place of LT in the treatment of NC-HCC
to be made.
Resection with extensive lymphadenectomy repre-
sents the only curative option for FL-HCC; without
surgery, the survival time ranges from only 9 to 14
months. Lymphadenectomy is necessary because
lymph node involvement is more frequent in compari-
son with HCC in patients with cirrhosis. This can be
explained by the fact that the tumor burden is usually
larger, and the hepatic lymph outflow remains present
in a normal liver parenchyma. The 5-year OS rate af-
ter surgery reaches 50% (range ¼ 32%-66%). Tumor
recurrence can occur late, even after 5 or 10 years,
and repeat hepatectomy (reported in 20%-60% of
patients) can significantly prolong survival.45,48 Vas-
cular involvement and lymph node involvement are
significant prognostic factors, but the tumor number,
the tumor size, and the use of chemotherapy are
not.48 The somewhat better results reported after
hepatectomy versus LT can be explained by the more
advanced tumor stages and immunosuppression in
liver recipients, as shown in the transplant series
from Hannover (8 patients),48 Birmingham, UK (9
patients),44 and Pittsburgh (13 patients).43 For
example, 90% of the Pittsburgh patients were deter-
mined to be stage IVA or IVB. The 5-year OS rates
for 28 resection patients and 13 transplant patients
were 88% and 36.3%, respectively; the 5- and 10-
year DFS rates were 33% and 30.8%, respectively.
The 5-year survival rate after recurrence was 28%.43
The 5-year OS rate of the partial hepatectomy series
from the Memorial Sloan-Kettering Cancer Center
(New York, NY), which included 28 patients, reached
56%.48 There is some indication that adjuvant chem-
otherapy (a combination of 5-fluorouracil and inter-
feron) may be useful and more applicable in these
patients because they present with normal residual
liver tissue.49,50
In conclusion, at the request of the consensus con-
ference committee, we have examined the reported
results of partial liver resection and transplantation
in NC-HCC patients. Although the reported experi-
ence, especially in the field of LT, is small, the (sur-
prisingly) high tumor recurrence rate after liver
resection and the few reports of successful outcomes
after LT for intrahepatic recurrence after partial
resection in these patients may indicate that NC-
HCC is an underused indication for LT. There is also
growing evidence that FL-HCC and (well-differenti-
ated) NC-HCC should be seen as a global entity and
not as 2 very different tumor variants for which LT
is exceptionally indicated. By enlarging the studied
patient cohorts, this approach would allow better
predictions to be made about the value of LT in
patients with NC-HCC. The analysis of the larger
ELTR series with 105 patients, which will be sub-
mitted in the very near future for publication, will
be a major step forward and will allow transplant
physicians to obtain better insight into this particu-
lar indication for LT. Appropriate patient selection
and perioperative care should provide these mostly
young patients access to potentially curative LT. Liv-
ing donor LT will undoubtedly play a more impor-
tant role in LT access for NC-HCC patients, who are
at a clear disadvantage in the Model for End-Stage
Liver Disease–based allocation system. In contrast
to patients with HCC and cirrhosis, the Milan crite-
ria and especially the tumor diameter do not seem
to play preponderant roles in the outcomes of these
patients. The most important factors for increased
recurrence in the studied patient cohorts are multi-
ple tumors, R0 resection, macrovascular invasion,
and lymph node invasion. These risk factors for
tumor recurrence must, therefore, be taken into
consideration in order to adequately select candi-
dates for LT. The ideal NC-HCC transplant candi-
date is that patient for whom, in the absence of
macrovascular and/or lymph node invasion, secure
R0 liver resection of a large tumor cannot be guar-
anteed and in whom 2 or more tumors have been
diagnosed. In the case of recurrent intrahepatic
HCC after resection, the time delay and the tumor
biology of the (available) resected specimen should
be taken into account in order to justify the indica-
tion for LT. In this context, it cannot be stressed
enough that transplantation as a treatment for any
kind of HCC includes both major surgery and immu-
nosuppressive medications. Adjuvant chemotherapy
and optimized immunosuppression (probably includ-
ing rapamycin) should be further explored in order to
improve the outcomes of LT in these particular recip-
ients.49-51 We hope that the results of the ongoing
SILVER study52 will confirm the experimentally pro-
ven antitumor properties of mammalian target of
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rapamycin inhibitors in the clinical transplant
setting.
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27. Bège T, Le Treut YP, Hardwigsen J, Ananian P, Richa H,
Campan P, Garcia S. Prognostic factors after resection
for hepatocellular carcinoma in nonfibrotic or moderately
fibrotic liver. A 116-case European series. J Gastrointest
Surg 2007;11:619-625.
28. Lubrano J, Huet E, Tsilividis B, François A, Goria O,
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